We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 32

CIPO updates guidance on medical use claims

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 23 2015

On March 18, 2015 the Canadian Intellectual Property Office issued a practice notice containing revised examination practice guidelines pertaining to

Expert opinion as to what “one would expect” is speculation, not evidence

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 4 2015

In the latest of a trilogy of cases under the Patented Medicines (Notice of Compliance) Regulations relating to the drug tadalafil (CIALIS), Justice

Canadian patent term extension is coming

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian

Biosimilar monoclonal antibodies emerge from the pipeline on both sides of the Atlantic

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • March 7 2014

The European Medicines Agency ("EMEA") made its biosimilar monoclonal antibody guidelines effective in December 20121. Less than a year later, in

Securing IP in stem cells

  • Bereskin & Parr LLP
  • -
  • Canada, USA
  • -
  • April 12 2013

Stem cells are at the centre of research into regenerative medicine. They have the ability to continuously produce newly differentiated cells and

Federal court considers “functionally” - limited claims in a biologic case

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • January 22 2014

The Federal Court of Canada recently issued a decision in AbbVie Corporation v. Janssen Inc.,2014 FC 55, involving infringement and validity of a

Licensing basics for life sciences: getting paid through license fees

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • February 28 2013

In life sciences, licensing fees are often upfront payments, ongoing royalties (usually a percentage of net sales) or milestone payments after a

Sufficiently disclosing a promised utility

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • June 28 2011

Pharmaceutical patent applicants are often confronted with the issue of whether to file a new drug patent application early or wait until more substantial data has been generated on a larger number of compounds

Europe discards embryonic stem cell patents

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • December 15 2011

Adult stem cells, and processes for their manipulation, are generally patentable in Europe

An update on Canadian selection patents the Olanzapine saga

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • December 15 2011

Eli Lilly’s Canadian patent no. 2,041,113 (‘113 patent), covering its successful drug Olanzapine, has been the subject of several court proceedings, including an infringement action which was appealed and subsequently remanded back to the trial division